Clinilabs Appoints Laura Shannon as CEO

Clinilabs, a specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, has appointed Laura Shannon as Chief Executive Officer (CEO) as Gary Zammit, Ph.D., the company’s founder, assumes the role of Executive Chairperson.

About Laura Shannon

Shannon offers more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive growth across complex organizations. Most recently, she served as EVP and Chief Commercial Officer of the U.S. and Canada regional business units at IQVIA. Throughout her career, Shannon has held broad global leadership roles across large and midsize pharma, emerging biopharma, and medtech companies.

“I am deeply honored to join Clinilabs as Chief Executive Officer,” said Shannon. “Gary and his team have built a truly differentiated, science-driven CRO with deep expertise in CNS drug and device development with a genuine commitment to developing therapies for patients. I am energized to lead this talented team with Gary and the rest of management to advance Clinilabs in its mission to bring better, safer, and more effective treatments to patients who need them most.”